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Background: Bone marrow-derived mesenchymal stem cells (BM-MSCs) and adipose tissue-derived mesenchymal
stem cells (AT-MSCs) are potential cellular sources of therapeutic stem cells. MSCs are a multipotent population of
cells capable of differentiating into a number of mesodermal lineages. Treatment using MSCs appears to be a
helpful approach for structural restoration in regenerative medicine. Correct identification of these cells is necessary,
but there is inadequate information on the MSC profile of cell surface markers and mRNA expression in dogs. In
this study, we performed molecular characterization of canine BM-MSCs and AT-MSCs using immunological and
mRNA expression analysis.
Results: Samples were confirmed to be multipotent based on their osteogenic and adipogenic differentiation. And
these cells were checked as stem cell, hematopoietic and embryonic stem cell (ESC) markers by flow cytometry.
BM- and AT-MSCs showed high expression of CD29 and CD44, moderate expression of CD90, and were negative
for CD34, CD45, SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81. SSEA-1 was expressed at very low levels in AT-MSCs.
Quantitative real-time PCR (qRT-PCR) revealed expression of Oct3/4, Sox2, and Nanog in BM- and AT-MSCs. There
was no significant difference in expression of Oct3/4 and Sox2 between BM-MSCs and AT-MSCs. However, Nanog
expression was 2.5-fold higher in AT-MSCs than in BM-MSCs. Using immunocytochemical analysis, Oct3/4 and Sox2
proteins were observed in BM- and AT-MSCs.
Conclusion: Our results provide fundamental information to enable for more reproducible and reliable quality
control in the identification of canine BM-MSCs and AT-MSCs by protein and mRNA expression analysis.
Keywords: Canine, Mesenchymal stem cell, Cell surface markers, Embryonic stem cell markersBackground
Mesenchymal stem cells (MSCs) have been successfully
isolated from bone marrow [1] and adipose tissue [2,3]
in humans. MSCs are multipotent and can differentiate
not only into cells of the mesodermal lineage, such as
osteoblasts [4], chondrocytes [5], and adipocytes [6], but
also into neurocytes [7] and cardiomyocytes [8]. Given
the appropriate microenvironment, MSCs can differenti-
ate into various tissues. Due to their accessibility,* Correspondence: tarai@nvlu.ac.jp
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reproduction in any medium, provided the orexpandability, and multipotentiality, MSCs hold promise
for applications in regenerative medicine [9,10].
MSCs are defined by their plastic adherent growth and
subsequent expansion under specific culture conditions
and by their in vitro and in vivo differentiation potential
[1-8]. Induction of differentiation into osteoblasts and adi-
pocytes under appropriate culture conditions has been ex-
tensively demonstrated [11]. However, MSC cultures are
composed of heterogeneous cell populations. The propor-
tion of pluripotent stem cells in bone marrow-derived
whole cell cultures ranged from 1/10,000 to 1/100,000
[12,13]. The lack of common standards and precise defin-
ition of initial cell preparations remains a major obstacle
in research on MSCs and their application. Current re-
search aims to characterize MSCs and to find ways ofral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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undifferentiated state [14-20].
The expression profile of cell surface markers and
mRNAs is well characterized in other species. In many
studies in humans and dogs CD29, CD44 and CD90
were regarded as positive cell-surface markers for MSCs
[14-17,21], while CD34 and CD45 were regard as nega-
tive surface markers [18-20,22]. In addition, stage-
specific embryonic antigen (SSEA)-1, SSEA-3, SSEA-4;
the keratin sulfate-associated antigen tumor-related anti-
gen (TRA)-1-60, and TRA-1-81 were reported as mar-
kers of canine embryonic stem cells (ESCs) [23]. These
molecules constitute a comprehensive set of unique
stem cell markers. Moreover, Oct3/4, Sox2, and Nanog
were shown to be important transcription factors regu-
lating ESC self-renewal and differentiation [24,25]. These
transcription factors interact with each other to oversee
a vast regulatory network that maintains pluripotency
and inhibited differentiation [24].
In veterinary medicine, the use of MSCs for tissue re-
pair is helpful and is likely to increase in future. How-
ever, there have been few studies on cell surface markers
and mRNA expression profiles of canine MSCs. Here we
evaluated the canine BM- and AT-MSC cell surface mar-
kers CD29, CD44, CD90, CD34, CD45, SSEA-1, SSEA-3,
SSEA-4, TRA-1-60, and TRA-1-81 by flow cytometry.
We also analyzed the mRNA expression profile of Oct3/
4, Sox2, and Nanog in canine BM- and AT-MSCs by
quantitative real-time PCR (qRT-PCR). Finally, we used










Figure 1 In vitro differentiation of BM-MSCs and AT-MSCs. Both types
differentiation was identified by von Kossa staining (C, D) and adipogeniclocalization of Oct3/4 and Sox2. The aim of this study
was the biological characterization of canine MSCs
isolated from bone marrow and adipose tissue.Results
Cell isolation and culture
Adherent cells were observed at the bottom of the cul-
ture flasks within 2 days; these cells were isolated from
both bone marrow and adipose tissue after plating. Bone
marrow-derived cells formed several colonies and prolif-
erated, taking various shapes, including discoidal flat,
triangular, and elongated (Figure 1A). Bone marrow-
derived cells were uniformly distributed immediately
after passage, but thereafter, gradually formed colonies
and proliferated. Unlike bone marrow-derived cells,
adipose-derived cells were uniformly distributed and no
colony formation was observed (Figure 1B).In vitro differentiation
Osteogenic differentiation was demonstrated histo-
chemically using von Kossa stain (Figure 1C, D). After
adipogenic induction culture for 3 weeks, MSCs showed
an adipogenic phenotype. Histochemical staining with
Oil Red O was used to demonstrate adipogenic differen-
tiation of MSCs. Lipid droplets were observed at about
14 days of culture in adipogenic medium and were posi-
tive for Oil Red O staining (Figure 1 E, F). Both differen-
tiation experiments were carried out in passage 2




of cell were maintained in control medium (A, B). Osteogenic
differentiation by Oil Red O staining (E, F). Scale bar, 200 μm.
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Cell surface antigen phenotyping was performed on BM-
and AT-MSCs by flow cytometry (Figure 2) (Table 1). BM-
MSCs and AT-MSCs revealed very similar expression pat-
terns of surface markers. Adhesion molecule protein CD29
(BM-MSCs, 98.41±0.53%; AT-MSCs, 97.85±0.94%), re-
ceptor molecule protein CD44 (BM-MSCs, 98.90±0.25%;
AT-MSCs, 97.85±0.85%), and thy-1 CD90 (BM-MSCs,
19.10±2.1%; AT-MSCs, 22.55±2.8%) were expressed in
both BM-MSCs (Figure 2A) and AT-MSCs (Figure 2B).
Both types of cells also expressed CD73 (BM-MSCs,Figure 2 Flow cytometry. Comparison of cell surface proteins CD29, CD4
on primary cultures of BM-MSCs (A, C) and AT-MSCs (B, D). Solid histogram
staining for the indicated marker. Three different donor MSC populations fr
shown.0.0081±0.0081%; AT-MSCs, 0.038±0.038%), CD105 (BM-
MSCs, 0.104±0.03%; AT-MSCs, 0.023±0.018%) (data
not shown).
Hematopoietic markers CD34 (BM-MSCs, 0.88±0.21%;
AT-MSCs, 0.25±0.06%) and CD45 (BM-MSCs, 0.24±0.07;
AT-MSCs, 0.17±0.02) were detected in BM-MSCs
(Figure 2A) and AT-MSCs (Figure 2B).
BM-MSCs (Figure 2C) and AT-MSCs (Figure 2D)
expressed the embryonic stem cell-specific markers SSEA-1
(BM-MSCs, 0.12±0.03%; AT-MSCs, 1.40±0.11%), SSEA-3
(BM-MSCs, 0.00±0.00%; AT-MSCs, 0.01±0.01%), SSEA-44, CD90, CD34, CD45, SSEA-1, SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81
s show nonspecific staining and open histograms show specific
om each tissue type were analyzed and representative samples are
Table 1 Summary of cell surface markers on canine BM-
and AT-MSCs
BM-MSCs AT-MSCs













Canine MSCs were analyzed by FACS, as shown in Figure 2. Samples were
scored as “−” if <9% of cells were positive, “+” if 9%–69% were positive, and
“++” if ≥70% were positive.
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60 (BM-MSCs, 0.01±0.00%; AT-MSCs, 0.02±0.01%),
and TRA-1-81 (BM-MSCs, 0.00±0.00%; AT-MSCs,
0.01±0.01%).mRNA expression analysis using quantitative real-time
PCR
Expression levels of canine Oct3/4, Sox2, and Nanog
mRNA in BM- and AT-MSCs were examined by qRT-
PCR (Figure 3). Expression of Oct3/4 did not differ sig-
nificantly difference between BM-MSCs and AT-MSCs.
However, Sox2 expression tended to be higher in BM-
MSCs than in AT-MSCs while Nanog expression in AT-
MSCs was 2.5-fold higher than in BM-MSCs. (p < 0.01).Figure 3 Quantitative RT-PCR. Expression levels of mRNAs for stem cell m
was normalized to beta-actin expression. Statistical comparisons were madImmunocytochemistry
Immunocytochemistry was used to analyze Oct3/4 and
Sox2 proteins (Figure 4). In both BM-MSCs and AT-
MSCs, Oct3/4 was detected mainly the nuclei, whereas
Sox2 was detected in the cytoplasm.Discussion
In this study, we confirmed the potential of MSCs to dif-
ferentiate into osteoblasts or adipocytes, and evaluated
the protein and mRNA expression profiles of these cells.
In addition, we compared the expression patterns of
ESC markers and germ layer markers in MSCs derived
from bone marrow and adipose tissue. BM-MSC
and AT-MSC populations expressed CD29, CD44, and
CD90 with similar intensity. In particular, in both BM-
and AT-MSCs, more than 95% of the cell population
expressed CD29 and CD44. Our results indicate that ex-
pression of CD90 was lower than that of other markers.
However, many human studies have reported strong ex-
pression of CD90. This may be related to differences
within species. Many human studies have reported posi-
tive expression of CD90 whereas many studies in mice
have reported negative expression of CD90 [11,26]. In
addition, the decline in CD90 expression may be influ-
enced by the passage number of the cells. In early passage
cells, CD90 showed variable expression [25,27-32], and
Riekstina et al. reported that CD90 expression decreased
with increasing passage number [33]. CD34 and CD45
markers are usually associated with hematopoietic stem
cells.
The qRT-PCR analysis revealed expression of the stem
cell markers Oct3/4, Sox2, and Nanog in canine BM-
and AT-MSCs. In a human study, mRNAs of these mar-
kers were expressed in human MSCs [34]. These tran-
scription factors mediate self-renewal and cell-fate
specification and are downregulated when the cells are
completely differentiated [35]. Our results reflect theirarkers Oct3/4, Sox2, and Nanog in BM-MSCs and AT-MSCs. Each value
e using Student’s t test (**p< 0.01).
Figure 4 Immunocytochemistry. Expression and localization of Oct3/4 and Sox2 in BM-MSCs and AT-MSCs. Immunofluorescent localization of
Oct3/4 in BM-MSCs with DAPI counterstaining (C, D). Immunofluorescent localization of Sox2 in BM-MSCs with DAPI counterstaining (E, F).
Immunofluorescent localization of Oct3/4 in AT-MSCs with DAPI counterstaining (I, J). Immunofluorescent localization of Oct3/4 in BM-MSCs with
DAPI counterstaining (K, L). Scale bar, 40 μm.
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pluripotent differentiation and support the hypothesis
that MSCs may be pluripotent stem cells deposited in
tissues during development. Oct3/4 mRNA showed
similar levels of expression in BM- and AT-MSCs. How-
ever, expression of Sox2 in BM-MSCs tended to be
higher than in AT-MSCs. Sox2 belongs to the Sox sub-
family, whose members are defined by the relationship
of their HMG box [36]. In addition, Sox2 regulates
Oct3/4 expression and maintains ESC pluripotency
through upstream transcription factors [37] and through
cooperative binding of OCT3/4 to DNA [38]. However,
our results indicate Oct3/4 expression was similar in
BM- and AT-MSCs, but Sox2 expression slightly differed
between the two cell types. This is probably due to the
additional expression of other Sox family members that
act in a compensatory in MSCs [37]. In addition, expres-
sion of Nanog in AT-MSCs was 2.5-fold higher than in
BM-MSCs. Nanog is required to maintain the undiffer-
entiated state and for the self-renewal of stem cells. In
ESCs, knockout or knockdown of Nanog abolishes both
self-renewal and pluripotency, and results in differenti-
ation of extraembryonic endoderm [39,40]. In a human
study, comparison of proliferation in BM- and AT-MSCs
revealed high proliferative ability in AT-MSCs [41].
These results suggest that AT-MSCs may maintain theundifferentiated state and that their self-renewal ability
is greater than that of BM-MSCs.
We performed immunostaining with Oct3/4 and Sox2
in MSCs. In both BM- and AT-MSCs, Oct3/4 was
detected in the nuclear fraction, whereas Sox2 was
detected in the cytoplasmic fraction. Several transcrip-
tion factors are known to be localized in the cytoplasmic
fraction, such as The Tead [42] and FOXO families [43].
These studies showed inhibitory activity of the transcrip-
tion factors. Hence it is possible that they inactivate
Sox2. In addition, Sox2 was localized in the nucleus in
canine ESCs [23]. There are many functional differences
between ESCs and MSCs. For example, ESCs form tera-
tomas in the testis, but MSCs do not. We therefore sug-
gest that restricted localization of Sox2 protein may lead
to lack of proliferation of MSCs in vivo as well as main-
tenance of pluripotency of MSCs in vitro.
Conclusion
Our study reveals the protein and mRNA expression
profiles of canine BM- and AT-MSCs. The two types of
cells showed similar cell surface marker profiles. Quanti-
tative real-time PCR revealed expression of mRNAs for
Oct3/4, Sox2, and Nanog in BM- and AT-MSCs. The
localization of Oct3/4 and Sox2 was demonstrated
immunocytochemically. mRNA expression of Nanog was
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are required to characterize canine MSCs with respect
to the expression of other proteins and mRNAs.
Methods
MSC isolation and culture
Four young healthy female beagle dogs (1 year old, 9.5-
11.3 kg body weight) were used. All animals were
anesthetized with propofor (Hospira, Osaka, Japan)
(7 mg/kg by intravenous injection) before tissue sample
were taken. After incubation, anesthesia was maintained
with isoflurane (1.5–2.0%) in oxygen. Animal experi-
ments were carried out in accordance with the National
Institutes of Health guidelines for the care and use of
laboratory animals. The protocol of this study was
approved by the University Committee for Animal
Experimentation.
BM-MSCs
Under general anesthesia, bone marrow was aspirated
from the proximal humerus using a general bone mar-
row biopsy technique. Briefly, a sterilized 13-gauge
Jamshidi needle (Cardinal Health, McGaw Park, USA)
was used to aspirate 5 ml of bone marrow into a syringe
containing 5 ml of heparinized (1,000 units/ml) saline
solution. Perioperative analgesic management was car-
ried out by the pre- and post-operative administration of
buprenorphine, which was administered twice daily for 3
consecutive days after surgery. In addition, ampicillin
(25 mg/kg) was orally administered twice daily for up to
7 days after surgery.
The bone marrow collected was dissociated and then
resuspended with a pipette. The suspension was centri-
fuged for 5 min at 300 × g and collected as a pellet. Mar-
row cells were then resuspended in 10 ml of 10% FBS–
PBS (FBS, Invitrogen, Carlsbad, USA; PBS, Invitrogen).
To obtain MSC-enriched nucleated cells, density separ-
ation (1.077 g/ml) was performed using Lymphoprep
(Axis-Shield, Oslo, Norway). A suspension of marrow
cells in FBS–PBS solution (10 ml) was carefully layered
onto 5 ml of Lymphoprep. Separation was achieved byTable 2 Primers used for qRT-PCR








β-actin CCCAGAGTCCATGACAATACCAGcentrifugation at 800 × g for 30 min at room
temperature. The nucleated cells collected from the PBS
solution - Lymphoprep interface were then washed in
PBS and transferred into T-75 cell culture flasks with
10 ml of control medium consisting of Dulbecco’s modi-
fied Eagle’s medium (Invitrogen), 10% FBS, and 1% anti-
biotic–antimycotic solution. Cells were plated at a
density of 1–5 × 107 cells/plate and incubated at 37°C in
a humidified 5% CO2 incubator and the medium was
changed twice weekly. When primary cultures reached
70%–80% confluency, attached cells were passaged by
exposure to 0.25% trypsin, 1 mM EDTA (Invitrogen) for
3 min, and replated at a density of 8.0 × 103 cells/cm2 for
subsequent passage.
AT-MSCs
Adipose tissues were also harvested from each dog
under general anesthesia. Subcutaneous fat pads (ap-
proximately 1.0 g) were harvested from the inguinal
area. These pads were finely minced with scissors and
then digested in 40 ml of PBS containing 0.15% collage-
nase (Invitrogen), with vigorous shaking for 60 min at
37°C. Samples were then filtered using 100 μm cell strai-
ners (BD Biosciences, Franklin Lakes, USA) and washed
with PBS. The cells obtained were seeded into T-75 cell
culture flasks with 10 ml of control medium and incu-
bated in the same manner as bone marrow cells.
In vitro differentiation
For osteogenic differentiation, passage 2 BM-MSCs and
AT-MSCs were plated on 6-well culture plates at a density
of 5.0 × 103 cells/cm2, and after incubation in control
medium for 24 h, the medium was changed to osteogenic
medium. The osteogenic medium was Canine Osteoblast
Differentiation Medium purchased from Cell Applications
(San Diego, USA). The medium was changed twice
weekly. For osteogenic analysis, mineral deposits were
quantitatively analyzed by von Kossa (Sigma, St. Louis,
USA) staining at 14 days.
For adipogenic differentiation, passage 2 BM- and AT-
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medium until confluency, and then the medium was
changed to Canine Adipocyte Differentiation Medium
(Cell Applications). The medium was changed twice in a
week. Oil Red O (Sigma) staining was performed to
analyze adipogenesis at 14 days.Flow cytometry
Passage 2 BM-MSCs and AT-MSCs were placed in
FACS tubes (BD Biosciences) at 2 × 105 cells/tube,
washed with FACS buffer (PBS containing 1% sodium
azide and 1% FBS, pH 7.2). The cells were incubated
with antibodies including CD29-PE (BioLegend, San
Diego, USA), CD34-PE (R&D Systems, Minneapolis,
USA), CD44-FITC (eBioscience, San Diego, USA),
CD90-PE (BD Biosciences), CD45 (Abcam, Cambridge,
UK) [44], CD73-PE (Bioss, Woburn, USA), CD105-FITC
(Bioss), SSEA-1 (R&D Systems), SSEA-3 (R&D Systems),
SSEA-4 (R&D Systems), TRA-1-60 (R&D Systems), and
TRA-1-81 (Chemicon, Temecula, USA) [21] at room
temperature for 1 h. The cells were washed twice with
FACS buffer and resuspended in 500 μl of FACS buffer.
The cells incubated with CD45, SSEA-1, SSEA-3, SSEA-
4, TRA-1-60, or TRA-1-81 were incubated with anti-rat
IgG, anti-rat IgM, anti-mouse IgG, and anti-mouse IgM
secondary antibodies labeled with FITC for 1 h. Cells
were then washed twice with FACS buffer and resus-
pended in 500 μl of FACS buffer. Cell fluorescence was
evaluated by flow cytometry in a FACSCalibur instru-
ment (BD Biosciences). Data were analyzed using Flowjo
software (Tree Star, Ashland, USA).Reverse transcription and quantitative real-time PCR
(qRT-PCR)
Total RNA was obtained from cultured BM-MSCs and
AT-MSCs in passage 2. Total RNA was extracted using
TRIzol reagent (Invitrogen) according to the manufac-
turer’s protocol. Total RNA was measured by spectro-
photometry. Total RNA (1 μg) was reverse-transcribed
at 42°C for 15 min in 20 μl with QuantiTect (Qiagen,
Düsseldorf, Germany) after inactivation of reverse tran-
scription by heating at 95°C for 3 min.
The cDNA product was subjected to real-time PCR
according to the user instructions for the Real-Time
PCR System 7300 (Applied Biosystems, Foster City, CA).
qRT-PCR was performed at 95°C for 5 s and 60°C for
34 s in 20 μl buffer containing SYBR premix ExTaq II
and ROX Reference Dye (Takara Bio, Shiga, Japan) and
0.2 μM each of the primers (Table 2). Quantitative meas-
urement was performed by establishing a linear amplifi-
cation curve from serial dilutions of plasmid DNA
containing each cDNA.Immunocytochemistry
Immunofluorescent staining was used to assess expres-
sion of the transcription factors Oct4, Sox2, and Nanog
in BM- and AT-MSCs. Passage 2 cells were cultured in
4-well chamber slides (Nunc, Roskilde, Denmark) until
50% confluency. The cells were washed twice with
PBS and fixed with 4% paraformaldehyde at room
temperature for 30 min. After washing thrice with PBS,
the cells were incubated with blocking solution contain-
ing 0.4% Triton X-100 and 4% Block Ace (DS Pharma
Biomedical, Osaka, Japan) in PBS at room temperature
for 1 h. The cells were incubated with rabbit polyclonal
primary antibodies against Oct3/4 (Santa Cruz Biotech-
nology, Santa Cruz, USA), Sox2 (Stem Cell Technolo-
gies, Vancouver, Canada), and Nanog (Peprotech, Rocky
Hill, USA) [21] diluted in blocking solution at 4°C for
16 h. The negative control cells were incubated without
primary antibody and isotype control cells were incu-
bated with normal rabbit IgG antibody (R&D Systems).
The cells were washed thrice with PBS and incubated
with secondary anti-rabbit antibody labeled with Alexa
Fluor 488 (Invitrogen) diluted in blocking solution at
room temperature for 1 h in darkness. The cells were
then washed thrice with PBS and slides were mounted
in Vectashield Hard Mounting Medium with DAPI
(Vector Laboratories, Burlingame, USA). The cells were
analyzed under a Zeiss Axiovert 200 M fluorescence
microscope (Carl Zeiss MicroImaging, Jena, Germany),
and image overlay was performed using Axio Vision
Rel.4.6 software (Carl Zeiss MicroImaging) (Additional
file 1: Table S1).
Statistical analysis
Data were analyzed with an independent samples t-test,
and a P-value of less than 0.01 was considered signifi-
cant. Statistical analysis was performed using Prism soft-
ware (GraphPad Software, San Diego, USA).
Additional file
Additional file 1: Table S1. Antibody Informations.
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